Acute Severe Ulcerative Colitis: Rescue Therapy Before the Surgeon Is Called
A single hospitalized patient with steroid-refractory acute severe ulcerative colitis, choosing a medical rescue agent against a genuine day-three deadline before colectomy becomes the default.
Marcus T., a 34-year-old man who works as a warehouse supervisor, has been in the hospital three days on intravenous methylprednisolone for what started as his usual ulcerative colitis flare and turned, over one bad weekend, into something the admitting team recognized immediately as acute severe disease — eleven bloody stools a day, a heart rate that won't settle under 100, and a CRP that's climbed rather than fallen since admission. He has had ulcerative colitis for six years, managed on mesalamine with two prior courses of oral steroids, never previously hospitalized and never on a biologic. His wife has been sleeping in the recliner beside his bed since Tuesday, and the surgical team has already been by once, not to operate today but to introduce themselves — standard practice on this unit once a patient crosses into steroid-refractory territory, so nobody is meeting a stranger if a colectomy conversation becomes necessary this week.
His day-three Oxford criteria are unambiguous: the rule is more than eight stools a day, or three to eight stools with a CRP above 45, and at eleven stools he clears the first arm outright without the CRP needing to be consulted at all — his rising CRP is confirmation, not the qualifying finding. That number matters beyond description — the Oxford criteria were derived specifically to identify, on day three, which patients on IV steroids are very unlikely to respond to more steroids and need a decision made now rather than a fourth day of waiting, and Marcus's own trajectory (worsening CRP, persistent tachycardia, stool frequency unchanged from admission) matches the pattern those criteria were built to catch.
The group's actual decision isn't whether to escalate — that part is settled — it's which rescue agent, medical or otherwise, actually gets him out of this admission without a colectomy, and how much runway that choice buys before the surgical conversation stops being a courtesy visit.
Day 3, the steroid-refractory conversation
Infliximab is the rescue agent I'd reach for. It's the most extensively studied option in this exact setting, the dosing is straightforward — a single infusion, no drug-level monitoring required before it takes effect — and unlike cyclosporine it can be continued seamlessly as maintenance therapy if it works, which matters for a biologic-naive patient we're hoping to keep out of the hospital long-term, not just get through this week.
I'm not arguing against medical rescue today — he doesn't meet criteria for urgent surgery right now, no perforation, no toxic megacolon. What I want on the record is that whichever agent gets chosen, the clock on reassessment needs to be real. The literature on steroid-refractory ASUC is consistent that patients who don't show meaningful improvement within roughly three to five days of rescue therapy have a colectomy rate that climbs sharply the longer that decision gets deferred — delayed surgery in a deteriorating patient carries real added morbidity.
I'd actually push back gently on the framing that cyclosporine buys less runway than infliximab — the CYSIF trial found the two agents statistically equivalent for short-term response in exactly this population, so the choice between them isn't really about which one is more likely to work.
The surgeon's citation is right, and it's actually the strongest argument for infliximab here, not against it. CYSIF found cyclosporine and infliximab statistically equivalent for response at day seven, which means efficacy isn't what should decide this — what should is which drug fits the patient once he responds. Cyclosporine requires therapeutic drug monitoring, carries real nephrotoxicity and hypertension risk, needs a normal cholesterol and magnesium to be used safely at all, and can't be continued as maintenance — it's a bridge to a thiopurine, with its own gap in coverage while that transition happens. Infliximab does everything cyclosporine does for this admission and then becomes his actual long-term regimen without a handoff. Tofacitinib has real emerging evidence as ASUC rescue too, but it's the least-studied of the three in this specific acute setting, and I wouldn't reach for the newest option first in a patient whose safety margin for experimentation is this narrow.
Agreed: infliximab 5mg/kg infused that afternoon, IV steroids continued through the response window, and an explicit day-three-post-infusion reassessment booked with the surgical team already looped in rather than paged fresh if it's needed. Not fully settled: how firm the reassessment deadline should be if he shows partial but incomplete improvement rather than a clean response or a clean failure — the surgeon wants a hard day-three cutoff regardless of trajectory, the gastroenterologist wants the option to extend to day five if the numbers are moving the right direction even slowly. Both plans stay on the chart; which one governs depends on what day three actually shows.